# PDUFA dates April 2026: FDA calendar and catalysts

Canonical: https://sec-api.dev/fda-calendar/2026-04

> 163 FDA catalysts are dated in April 2026, including 20 PDUFA dates.

Data as of November 16, 2026 (snapshot 20261116T222116Z). Every date quotes the SEC filing or FDA page it came from. Date precision: exact day, month only.

**Free:** every drug page and the next 30 days of the FDA calendar, no account. Calendar API, alerts when a date moves, and full history: https://sec-api.dev/pricing . Free API key: https://sec-api.dev/sign-up?ref=ai-claudebot

## Verified answer

### What PDUFA dates are in April 2026?

PDUFA dates in April 2026: SPINRAZA (nusinersen, BIIB) on April 3, 2026; tividenofusp (DNLI) on April 5, 2026; tividenofusp alfa (DNLI) on April 5, 2026; KEYTRUDA® (pembrolizumab, MRK) on April 7, 2026; doxorubicin (BMY) on April 8, 2026; vusolimogene oderparepvec (REPL) on April 10, 2026; and 14 more. [Calendar and source filings](https://sec-api.dev/fda-calendar/2026-04)

Source: Press release filed with the SEC (EX-99), accession 0000875045-25-000047, https://www.sec.gov/Archives/edgar/data/875045/000087504525000047/exhibit991-q32025pressrele.htm (retrieved 2026-11-12). Last confirmed 2026-02-26. Cite: https://sec-api.dev/fda-calendar/2026-04#answer

## PDUFA dates in April 2026

Data as of November 16, 2026.

| PDUFA date | Company | Ticker | Drug | Indication | Source |
| --- | --- | --- | --- | --- | --- |
| April 3, 2026 | BIOGEN INC. | BIIB | SPINRAZA (nusinersen) |  | [Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/875045/000087504525000047/exhibit991-q32025pressrele.htm) |
| April 5, 2026 | Denali Therapeutics Inc. | DNLI | tividenofusp |  | [Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1714899/000171489925000209/a20251204-denaliinvestor.htm) |
| April 5, 2026 | Denali Therapeutics Inc. | DNLI | tividenofusp alfa |  | [Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1714899/000171489926000020/ex991pressreleaseq42025.htm) |
| April 7, 2026 | Merck & Co., Inc. | MRK | KEYTRUDA® (pembrolizumab) |  | [SEC Form 10-Q](https://www.sec.gov/Archives/edgar/data/310158/000031015825000059/mrk-20250930.htm) |
| April 8, 2026 | BRISTOL MYERS SQUIBB CO | BMY | doxorubicin |  | [SEC Form 10-K](https://www.sec.gov/Archives/edgar/data/14272/000001427226000004/bmy-20251231.htm) |
| April 10, 2026 | Replimune Group, Inc. | REPL | vusolimogene oderparepvec |  | [Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1737953/000110465926009510/tm264822d1_ex99-1.htm) |
| April 10, 2026 | Replimune Group, Inc. | REPL | Opdivo® (nivolumab) | advanced melanoma | [SEC Form 8-K](https://www.sec.gov/Archives/edgar/data/1737953/000110465925100605/tm2529069d1_8k.htm) |
| April 13, 2026 | Travere Therapeutics, Inc. | TVTX |  |  | [SEC Form 10-K](https://www.sec.gov/Archives/edgar/data/1438533/000143853326000014/tvtx-20251231.htm) |
| April 13, 2026 | LIGAND PHARMACEUTICALS INC | LGND | rapamycin |  | [Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/886163/000088616326000003/q42025earningsrelease_ex991.htm) |
| April 13, 2026 | Travere Therapeutics, Inc. | TVTX | FILSPARI (sparsentan) |  | [Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1438533/000143853326000013/aex991_2025q4x10xkearnings.htm) |
| April 23, 2026 | Grace Therapeutics, Inc. | GRCE |  |  | [SEC Form 10-Q](https://www.sec.gov/Archives/edgar/data/1444192/000114036126004924/ef20060621_10q.htm) |
| April 23, 2026 | Grace Therapeutics, Inc. | GRCE | GTX-104 | aSAH | [Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1444192/000114036126004927/ef20064916_ex99-1.htm) |
| April 23, 2026 | Sanofi | SNY |  |  | [Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1121404/000119312525250744/d69958dex993.htm) |
| April 23, 2026 | IONIS PHARMACEUTICALS INC | IONS | onasemnogene abeparvovec |  | [SEC Form 10-K](https://www.sec.gov/Archives/edgar/data/874015/000087401526000115/form10k.htm) |
| April 27, 2026 | Sanofi | SNY |  |  | [Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1121404/000119312525250744/d69958dex993.htm) |
| April 28, 2026 | Merck & Co., Inc. | MRK | IDVYNSO (doravirine-islatravir) |  | [SEC Form 10-K](https://www.sec.gov/Archives/edgar/data/310158/000031015826000063/mrk-20251231.htm) |
| April 29, 2026 | Sanofi | SNY |  |  | [Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1121404/000112140426000001/pressreleaseq42025english.htm) |
| April 29, 2026 | LIGAND PHARMACEUTICALS INC | LGND | rapamycin |  | [Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/886163/000088616326000003/q42025earningsrelease_ex991.htm) |
| April 30, 2026 | Axsome Therapeutics, Inc. | AXSM | SYMBRAVO® (meloxicam-rizatriptan) |  | [Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1579428/000119312526062421/axsm-ex99_1.htm) |
| April 30, 2026 | Axsome Therapeutics, Inc. | AXSM | AUVELITY (dextromethorphan-bupropion) |  | [Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1579428/000119312526062421/axsm-ex99_1.htm) |

## All catalysts in April 2026

| Date | Event | Ticker | Indication | Status | Source sentence |
| --- | --- | --- | --- | --- | --- |
| April 1, 2026 | [IGALMI® (dexmedetomidine) NDA/BLA acceptance](https://sec-api.dev/pdufa/dexmedetomidine) | BTAIQ |  | completed | "On April 1, 2026, we announced that the FDA has accepted our sNDA for approval of IGALMI® for at-home use in the acute treatment of agitation associated with bipolar disorders or schizophrenia." ([SEC Form 10-Q](https://www.sec.gov/Archives/edgar/data/1720893/000110465926095965/btai-20260630x10q.htm)) |
| April 1, 2026 | [TuHURA Biosciences, Inc./NV earnings report](https://sec-api.dev/companies/hura/catalysts) | HURA |  | completed | "TuHURA Biosciences Reports Fourth Quarter and Full Year 2025 Financial Results and Provides a Corporate Update" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1498382/000119312526135766/hura-ex99_1.htm)) |
| April 1, 2026 | [NEONC TECHNOLOGIES HOLDINGS, INC. earnings report](https://sec-api.dev/companies/nthi/catalysts) | NTHI |  | completed | "Provides Business Update and Reports Q4 2025 Financial Results" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1979414/000182912626003165/neonctechnologies_ex99-1.htm)) |
| April 1, 2026 | [Treprostinil palmitil inhalation powder primary completion](https://sec-api.dev/pdufa/treprostinil-palmitil-inhalation-powder) | INSM | Pulmonary Hypertension; Interstitial Lung Disease | completed | "NCT05649722 (An Extension Study of Treprostinil Palmitil Inhalation Powder (TPIP) for Pulmonary Hypertension Associated With Interstitial Lung Disease (PH-ILD)): Overall Status COMPLETED; Phase PHASE2, PHASE3; Primary Completion 2026-04-01 (ACTUAL); Lead Sponsor Insmed Incorporated." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT05649722)) |
| April 2026 | [Open-label rusfertide primary completion](https://sec-api.dev/pdufa/open-label-rusfertide) | PTGX | Polycythemia Vera | delayed | "NCT06033586 (Study to Evaluate the Long-term Safety of Rusfertide (PTG-300) in Subjects With Polycythemia Vera): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2026-04-01 (ESTIMATED); Lead Sponsor Protagonist Therapeutics, Inc.." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06033586)) |
| April 1, 2026 | [Talquetamab primary completion](https://sec-api.dev/pdufa/talquetamab) | JNJ | Multiple Myeloma | completed | "NCT06208150 (A Study Comparing Talquetamab Plus Pomalidomide, Talquetamab Plus Teclistamab, and Elotuzumab, Pomalidomide, and Dexamethasone or Pomalidomide, Bortezomib, and Dexamethasone in Participants With Relapsed or Refractory Myeloma Who Have Received an Anti-CD38 Antibody and Lenalidomide): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2026-04-01 (ACTUAL); Lead Sponsor Janssen Research & Development, LLC." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06208150)) |
| April 1, 2026 | [Foundayo (orforglipron calcium) FDA approval](https://sec-api.dev/pdufa/orforglipron) | LLY |  | completed, approved | "Foundayo \| orforglipron \| 4/1/2026 \| To reduce excess body weight and maintain weight reduction long term in adults with obesity or adults with overweight in the presence of at least one weight-related comorbid condition, in combination with a reduced-calorie diet and increased physical activity" ([FDA novel drug approvals](https://www.fda.gov/drugs/novel-drug-approvals-fda/novel-drug-approvals-2026)) |
| April 2, 2026 | [FAYUVI (rebisufligene etisparvovec) NDA/BLA acceptance](https://sec-api.dev/pdufa/rebisufligene-etisparvovec) | RARE | Sanfilippo syndrome Type A | completed | "On April 2, 2026, Ultragenyx Pharmaceutical Inc. (the "Company") issued a press release announcing that the U.S. Food and Drug Administration (the "FDA") has accepted for review the Company's resubmitted Biologics License Application seeking accelerated approval for UX111 (rebisufligene etisparvovec) AAV9 gene therapy as a treatment for patients with Sanfilippo syndrome Type A (MPS IIIA)." ([SEC Form 8-K](https://www.sec.gov/Archives/edgar/data/1515673/000119312526139084/rare-20260402.htm)) |
| April 2, 2026 | [PAVBLU® (aflibercept) label expansion decision](https://sec-api.dev/pdufa/aflibercept) | REGN |  | completed, approved | "BLA761355 SUPPL-5 (Efficacy): submission_status AP, submission_status_date 20260402, review_priority STANDARD; sponsor_name REGENERON PHARMACEUTICALS; product EYLEA HD (AFLIBERCEPT)." ([openFDA Drugs@FDA](https://api.fda.gov/drug/drugsfda.json?search=application_number:%22BLA761355%22)) |
| April 2, 2026 | [Batoclimab primary completion](https://sec-api.dev/pdufa/batoclimab) | IMVT | Thyroid Eye Disease | withdrawn | "NCT05517447 (Extension Study to Assess Batoclimab in Participants With Thyroid Eye Disease): Overall Status TERMINATED; Phase PHASE3; Primary Completion 2026-04-02 (ACTUAL); Lead Sponsor Immunovant Sciences GmbH." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT05517447)) |
| April 2, 2026 | [Dexamethasone ophthalmic suspension (ocs-01) primary completion](https://sec-api.dev/pdufa/dexamethasone-ophthalmic-suspension-ocs-01) | OCS | Diabetic Macular Edema | completed | "NCT06172257 (A Pivotal Safety and Efficacy Study of OCS-01 Eye Drops in Participants With Diabetic Macular Edema (DIAMOND 2)): Overall Status COMPLETED; Phase PHASE3; Primary Completion 2026-04-02 (ACTUAL); Lead Sponsor Oculis." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06172257)) |
| April 2, 2026 | [Tulisokibart primary completion](https://sec-api.dev/pdufa/tulisokibart) | MRK | Hidradenitis Suppurativa | completed | "NCT06956235 (Study to Evaluate Tulisokibart for Hidradenitis Suppurativa (MK-7240-012)): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE2; Primary Completion 2026-04-02 (ACTUAL); Lead Sponsor Merck Sharp & Dohme LLC." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06956235)) |
| April 3, 2026 | [SPINRAZA (nusinersen) PDUFA date](https://sec-api.dev/pdufa/nusinersen) | BIIB |  | completed, approved | "•Today announced that high dose nusinersen (SPINRAZA) in SMA was successfully resubmitted with the FDA with an updated PDUFA date of April 3, 2026" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/875045/000087504525000047/exhibit991-q32025pressrele.htm)) |
| April 3, 2026 | [Botox Cosmetic (onabotulinumtoxina) primary completion](https://sec-api.dev/pdufa/onabotulinumtoxina) | ABBV | Forehead Lines | completed | "NCT06794866 (A Study to Assess Adverse Events and Effectiveness of OnabotulinumtoxinA Intramuscular Injections for the Change of Moderate to Severe Forehead Lines in Adult Participants): Overall Status COMPLETED; Phase PHASE3; Primary Completion 2026-04-03 (ACTUAL); Lead Sponsor AbbVie." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06794866)) |
| April 5, 2026 | [Tividenofusp PDUFA date](https://sec-api.dev/pdufa/tividenofusp) | DNLI |  | scheduled | "58 Tividenofusp Alfa Development and Regulatory Path Robust data package supporting a target indication for the full MPS II phenotype spectrum PDUFA Target Action Date: April 5, 2026 Preparing for Commercial Launch" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1714899/000171489925000209/a20251204-denaliinvestor.htm)) |
| April 5, 2026 | [Tividenofusp alfa PDUFA date](https://sec-api.dev/pdufa/tividenofusp-alfa) | DNLI |  | completed, approved | "•Tividenofusp alfa (DNL310; ETV:IDS) launch readiness established ahead of April 5, 2026 Prescription Drug User Fee Act (PDUFA) target action date for Hunter syndrome" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1714899/000171489926000020/ex991pressreleaseq42025.htm)) |
| April 5, 2026 | [Certepetide primary completion](https://sec-api.dev/pdufa/certepetide) | LSTA | Cholangiocarcinoma; Gallbladder Cancer; Gallbladder Carcinoma | completed | "NCT05712356 (A Study of LSTA1 When Added to Standard of Care Versus Standard of Care Alone in Patients With Advanced Solid Tumors): Overall Status COMPLETED; Phase PHASE2; Primary Completion 2026-04-05 (ACTUAL); Lead Sponsor Lisata Therapeutics, Inc.; Results First Posted 2026-05-26." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT05712356)) |
| April 6, 2026 | [Cendakimab topline data readout](https://sec-api.dev/pdufa/cendakimab) | BMY | Eosinophilic Esophagitis | completed | "NCT04991935 (Safety Study of CC-93538 in Adult and Adolescent Participants With Eosinophilic Esophagitis): Overall Status COMPLETED; Phase PHASE3; Primary Completion 2025-08-14 (ACTUAL); Lead Sponsor Celgene; Results First Posted 2026-04-06." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT04991935?tab=results)) |
| April 6, 2026 | [Retatrutide primary completion](https://sec-api.dev/pdufa/retatrutide) | LLY | Obesity; Overweight; Osteoarthritis, Knee | completed | "NCT05929066 (A Study of Retatrutide (LY3437943) in Participants Who Have Obesity or Overweight): Overall Status COMPLETED; Phase PHASE3; Primary Completion 2026-04-06 (ACTUAL); Lead Sponsor Eli Lilly and Company." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT05929066)) |
| April 6, 2026 | [Auxora primary completion](https://sec-api.dev/pdufa/auxora) | CALC | Acute Kidney Injury | withdrawn | "NCT06374797 (A Study of Auxora in Patients With AKI and Injurious Lung "Crosstalk"): Overall Status TERMINATED; Phase PHASE2; Primary Completion 2026-04-06 (ACTUAL); Lead Sponsor CalciMedica, Inc.." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06374797)) |
| April 6, 2026 | [Netarsudil 0.01%/latanoprost 0.005% ophthalmic solution primary completion](https://sec-api.dev/pdufa/netarsudil-0-01-latanoprost-0-005) | ALC | Ocular Hypertension; Open Angle Glaucoma | completed | "NCT07082816 (Reformulated PG324 Ophthalmic Solution for Intraocular Pressure Reduction): Overall Status COMPLETED; Phase PHASE3; Primary Completion 2026-04-06 (ACTUAL); Lead Sponsor Alcon Research." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07082816)) |
| April 7, 2026 | [Jaguar Health, Inc. earnings report](https://sec-api.dev/companies/jagx/catalysts) | JAGX |  | completed | "(NASDAQ: JAGX) ("Jaguar" or the "Company") today reported its consolidated fourth-quarter 2025 financial results." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1585608/000119312526144604/d111491dex991.htm)) |
| April 7, 2026 | [KEYTRUDA® (pembrolizumab) PDUFA date](https://sec-api.dev/pdufa/pembrolizumab) | MRK |  | scheduled | "The FDA set a PDUFA date of April 7, 2026, marking the first concurrent review of both Keytruda and Keytruda Qlex for the same novel indication." ([SEC Form 10-Q](https://www.sec.gov/Archives/edgar/data/310158/000031015825000059/mrk-20250930.htm)) |
| April 7, 2026 | [EVX-01 primary completion](https://sec-api.dev/pdufa/evx-01) | EVAX | Melanoma Stage IV; Unresectable Melanoma | completed | "NCT05309421 (A Single Arm Trial Evaluating the Efficacy and Safety of EVX-01 in Combination With Pembrolizumab in Adults With Unresectable or Metastatic Melanoma): Overall Status COMPLETED; Phase PHASE2; Primary Completion 2026-04-07 (ACTUAL); Lead Sponsor Evaxion Biotech A/S." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT05309421)) |
| April 8, 2026 | [Doxorubicin PDUFA date](https://sec-api.dev/pdufa/doxorubicin) | BMY |  | scheduled | "The FDA assigned a PDUFA goal date of April 8, 2026." ([SEC Form 10-K](https://www.sec.gov/Archives/edgar/data/14272/000001427226000004/bmy-20251231.htm)) |
| April 8, 2026 | [Nurix Therapeutics, Inc. earnings report](https://sec-api.dev/companies/nrix/catalysts) | NRIX |  | completed | "Nurix Therapeutics Reports First Quarter 2026 Financial Results and Provides a Corporate Update" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1549595/000154959526000024/nrix-20260408xexx991.htm)) |
| April 9, 2026 | [ImmunityBio, Inc. earnings report](https://sec-api.dev/companies/ibrx/catalysts) | IBRX |  | completed | "CULVER CITY, Calif., Apr. 9, 2026 — ImmunityBio, Inc. (NASDAQ: IBRX), a commercial-stage biotechnology company, announced today preliminary select operational results for the fiscal quarter ending March 31, 2026." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1326110/000132611026000036/ibrx-2026498xkexhibit991.htm)) |
| April 9, 2026 | [ONUREG (azacitidine) label expansion decision](https://sec-api.dev/pdufa/azacitidine) | BMY |  | completed, approved | "NDA214120 SUPPL-3 (Efficacy): submission_status AP, submission_status_date 20260409, review_priority STANDARD; sponsor_name BRISTOL; product ONUREG (AZACITIDINE)." ([openFDA Drugs@FDA](https://api.fda.gov/drug/drugsfda.json?search=application_number:%22NDA214120%22)) |
| April 9, 2026 | [Cipargamin topline data readout](https://sec-api.dev/pdufa/cipargamin) | NVS | Severe Malaria | completed | "NCT04675931 (To Evaluate Efficacy, Safety, Tolerability and PK of Intravenous Cipargamin in Participants With Severe Plasmodium Falciparum Malaria): Overall Status COMPLETED; Phase PHASE2; Primary Completion 2025-07-24 (ACTUAL); Lead Sponsor Novartis Pharmaceuticals; Results First Posted 2026-04-09." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT04675931?tab=results)) |
| April 9, 2026 | [Frespaciguat primary completion](https://sec-api.dev/pdufa/frespaciguat) | MRK | Pulmonary Hypertension; Chronic Obstructive Pulmonary Disease | completed | "NCT05612035 (Frespaciguat (MK-5475) INSIGNIA-PH-COPD: A Study of the Efficacy and Safety of Frespaciguat (an Inhaled sGC Stimulator) in Adults With PH-COPD): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE2; Primary Completion 2026-04-09 (ACTUAL); Lead Sponsor Merck Sharp & Dohme LLC." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT05612035)) |
| April 10, 2026 | [DA-1726 trial start](https://sec-api.dev/pdufa/da-1726) | MTVA |  | completed | "On April 10, 2026, MetaVia Inc. (the "Company") issued a press release announcing that the first patient has been dosed in Part 3 of its Phase 1 clinical trial evaluating DA-1726, a novel dual oxyntomodulin (OXM) analog targeting both GLP-1 (GLP1R) and glucagon (GCGR) receptors." ([SEC Form 8-K](https://www.sec.gov/Archives/edgar/data/1638287/000110465926041784/mtva-20260410x8k.htm)) |
| April 10, 2026 | [Vusolimogene oderparepvec PDUFA date](https://sec-api.dev/pdufa/vusolimogene-oderparepvec) | REPL |  | completed, complete response letter | "Act (PDUFA) target action date of April 10, 2026." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1737953/000110465926009510/tm264822d1_ex99-1.htm)) |
| April 10, 2026 | [Opdivo® (nivolumab) PDUFA date](https://sec-api.dev/pdufa/nivolumab) | REPL | advanced melanoma | completed, complete response letter | "The PDUFA date set by the FDA is April 10, 2026 based on a Class II resubmission timeline." ([SEC Form 8-K](https://www.sec.gov/Archives/edgar/data/1737953/000110465925100605/tm2529069d1_8k.htm)) |
| April 10, 2026 | [Bla761401 complete response letter (CRL)](https://sec-api.dev/pdufa/bla761401) | TLX |  | completed, complete response letter | "We have completed our review of this application and have determined that we cannot approve this application in its present form." ([FDA complete response letter database](https://api.fda.gov/transparency/crl.json?search=file_name:%22CRL_BLA761401_20260410.pdf%22)) |
| April 10, 2026 | [Opdivo® (nivolumab) complete response letter (CRL)](https://sec-api.dev/pdufa/nivolumab) | REPL | advanced melanoma | completed, complete response letter | "On April 10, 2026 the Company received a CRL from the FDA for the BLA for RP1 in combination with nivolumab for the treatment of advanced melanoma." ([SEC Form 10-K](https://www.sec.gov/Archives/edgar/data/1737953/000162828026045886/repl-20260331.htm)) |
| April 10, 2026 | [Dexamethasone ophthalmic suspension (ocs-01) primary completion](https://sec-api.dev/pdufa/dexamethasone-ophthalmic-suspension-ocs-01) | OCS | Diabetic Macular Edema | completed | "NCT05066997 (A Pivotal Safety and Efficacy Study of OCS-01 Eye Drops in Participants With Diabetic Macular Edema (DIAMOND 1)): Overall Status COMPLETED; Phase PHASE2, PHASE3; Primary Completion 2026-04-10 (ACTUAL); Lead Sponsor Oculis." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT05066997)) |
| April 10, 2026 | [Vusolimogene oderparepvec complete response letter (CRL)](https://sec-api.dev/pdufa/vusolimogene-oderparepvec) | REPL |  | completed, complete response letter | "COMPLETE RESPONSE letter dated 04/10/2026 for BL 125827 to Replimune, Inc.." ([FDA complete response letter database](https://api.fda.gov/transparency/crl.json?search=file_name:%22CRL_BLA125827_20260410.pdf%22)) |
| April 11, 2026 | [FABHALTA® (iptacopan) primary completion](https://sec-api.dev/pdufa/iptacopan) | NVS | Atypical Hemolytic Uremic Syndrome | completed | "NCT04889430 (Efficacy and Safety of Iptacopan (LNP023) in Adult Patients With Atypical Hemolytic Uremic Syndrome Naive to Complement Inhibitor Therapy): Overall Status COMPLETED; Phase PHASE3; Primary Completion 2026-04-11 (ACTUAL); Lead Sponsor Novartis Pharmaceuticals." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT04889430)) |
| April 13, 2026 | [ONP-002 trial start](https://sec-api.dev/pdufa/onp-002) | OGEN | concussion and mild traumatic brain injury | completed | "Fla., April 13, 2026 — Oragenics, Inc. (NYSE American: OGEN), a clinical-stage biotechnology company developing brain-targeted therapeutics through proprietary intranasal delivery technology, today announced that the first patient has been dosed in its ongoing" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1174940/000149315226016294/ex99-1.htm)) |
| April 13, 2026 | [FILSPARI (sparsentan) FDA approval](https://sec-api.dev/pdufa/sparsentan) | TVTX |  | completed, approved | "On April 13, 2026, Travere Therapeutics, Inc. (the "Company") announced that the U.S. Food and Drug Administration ("FDA") has approved FILSPARI® (sparsentan) to reduce proteinuria in adult and pediatric patients aged 8 years and older with focal segmental glomerulosclerosis ("FSGS") without nephrotic syndrome." ([SEC Form 8-K](https://www.sec.gov/Archives/edgar/data/1438533/000143853326000032/tvtx-20260413.htm)) |
| April 13, 2026 | [Travere Therapeutics, Inc. PDUFA date](https://sec-api.dev/companies/tvtx/catalysts) | TVTX |  | scheduled | "In January 2026, we announced that the FDA extended the review timeline for the sNDA, and the new PDUFA target action date is April 13, 2026." ([SEC Form 10-K](https://www.sec.gov/Archives/edgar/data/1438533/000143853326000014/tvtx-20251231.htm)) |
| April 13, 2026 | [SPY001 topline data readout](https://sec-api.dev/pdufa/spy001) | SYRE | moderate-to-severely active UC | completed, positive | "On April 13, 2026, the Company announced positive initial 12-week induction topline data from Part A of the Phase 2 SKYLINE trial of SPY001 for the treatment of moderate-to-severely active UC." ([SEC Form 8-K](https://www.sec.gov/Archives/edgar/data/1636282/000162828026024831/syre-20260413.htm)) |
| April 13, 2026 | [Rapamycin PDUFA date](https://sec-api.dev/pdufa/rapamycin) | LGND |  | scheduled | "The new Prescription Drug User Fee Act (PDUFA) target action date is April 13, 2026." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/886163/000088616326000003/q42025earningsrelease_ex991.htm)) |
| April 13, 2026 | [FILSPARI (sparsentan) PDUFA date](https://sec-api.dev/pdufa/sparsentan) | TVTX |  | completed, approved | "PDUFA target action date for FILSPARI in FSGS is April 13, 2026; Company positioned for a successful commercial launch, if approved" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1438533/000143853326000013/aex991_2025q4x10xkearnings.htm)) |
| April 13, 2026 | [Dexilant Solutab (dexlansoprazole) primary completion](https://sec-api.dev/pdufa/dexlansoprazole) | TAK | Erosive Esophagitis | withdrawn | "NCT02615184 (A Study to Check the Safety of Dexlansoprazole and Learn If it Can Heal Erosive Esophagitis (EE) and Keep it Healed in Children 2 to 11 Years Old): Overall Status TERMINATED; Phase PHASE2; Primary Completion 2026-04-13 (ACTUAL); Lead Sponsor Takeda." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT02615184)) |
| April 13, 2026 | [Pomalyst (pomalidomide) primary completion](https://sec-api.dev/pdufa/pomalidomide) | BMY | Multiple Myeloma | completed | "NCT03651128 (Efficacy and Safety Study of bb2121 Versus Standard Regimens in Subjects With Relapsed and Refractory Multiple Myeloma (RRMM)): Overall Status COMPLETED; Phase PHASE3; Primary Completion 2026-04-13 (ACTUAL); Lead Sponsor Celgene." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT03651128)) |
| April 13, 2026 | [FILSPARI (sparsentan) label expansion decision](https://sec-api.dev/pdufa/sparsentan) | TVTX |  | completed, approved | "NDA216403 SUPPL-6 (Efficacy): submission_status AP, submission_status_date 20260413, review_priority STANDARD; sponsor_name TRAVERE; product FILSPARI (SPARSENTAN)." ([openFDA Drugs@FDA](https://api.fda.gov/drug/drugsfda.json?search=application_number:%22NDA216403%22)) |
| April 14, 2026 | [FASPRO (daratumumab-hyaluronidase) FDA approval](https://sec-api.dev/pdufa/daratumumab-hyaluronidase) | JNJ |  | completed, approved | "Johnson & Johnson Announces U.S. FDA Approval of TECVAYLI plus DARZALEX FASPRO for Relapsed/Refractory Multiple Myeloma, Offering a Potential New Standard of Care as Early as Second Line" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/200406/000020040626000076/a2026q1exhibit991.htm)) |
| April 14, 2026 | [Praxis Precision Medicines, Inc. NDA/BLA acceptance](https://sec-api.dev/companies/prax/catalysts) | PRAX | essential tremor in adults | completed | "On April 14, 2026, Praxis Precision Medicines, Inc. announced that the U.S. Food and Drug Administration (the "FDA") has accepted for review its New Drug Application for ulixacaltamide HCl for the treatment of essential tremor in adults." ([SEC Form 8-K](https://www.sec.gov/Archives/edgar/data/1689548/000168954826000033/prax-20260414.htm)) |
| April 14, 2026 | [Oms906 study drug primary completion](https://sec-api.dev/pdufa/oms906-study-drug) | OMER | C3 Glomerulopathy; Idiopathic Immune Complex-Mediated Glomerulonephritis | withdrawn | "NCT06209736 (Safety and Efficacy Study of OMS906 in Patients With C3G and ICGN): Overall Status TERMINATED; Phase PHASE2; Primary Completion 2026-04-14 (ACTUAL); Lead Sponsor Omeros Corporation." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06209736)) |
| April 15, 2026 | [GeoVax Labs, Inc. earnings report](https://sec-api.dev/companies/govx/catalysts) | GOVX |  | completed | "GeoVax Reports 2025 Year-End Financial Results and Provides Business Update" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/832489/000143774926012435/ex_945907.htm)) |
| April 15, 2026 | [Traws Pharma, Inc. earnings report](https://sec-api.dev/companies/traw/catalysts) | TRAW |  | completed | "Company"), a clinical-stage biopharmaceutical company developing novel therapies to target critical threats to human health from respiratory viral diseases, today reported financial results for the year ended December 31, 2025 and provided recent business highlights including updates for the Company's lead investigational program: tivoxavir marboxil (TXM) in development for influenza prophylaxis and treatment, and completion of a private investment in public equity (PIPE) financing providing up to $60 million in gross proceeds, including $10 million in gross proceeds at closing." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1130598/000110465926043781/tm2611843d2_ex99-1.htm)) |
| April 15, 2026 | [WAINUA (eplontersen) label expansion decision](https://sec-api.dev/pdufa/eplontersen) | AZN |  | completed, approved | "NDA217388 SUPPL-5 (Efficacy): submission_status AP, submission_status_date 20260415, review_priority STANDARD; sponsor_name ASTRAZENECA AB; product WAINUA (AUTOINJECTOR) (EPLONTERSEN SODIUM)." ([openFDA Drugs@FDA](https://api.fda.gov/drug/drugsfda.json?search=application_number:%22NDA217388%22)) |
| April 15, 2026 | [Tivicay (dolutegravir sodium) primary completion](https://sec-api.dev/pdufa/dolutegravir) | GSK | HIV; HIV Infections | completed | "NCT05979311 (A Study to Evaluate the Efficacy, Safety, and Tolerability of Using an Oral Once-daily 2 Drug Regimen Compared to an Oral Once-daily 3 Drug Regimen for the Treatment of Human Immunodeficiency Virus (HIV)-1 in Adults Who Have Not Previously Taken Antiretroviral Therapy): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2026-04-15 (ACTUAL); Lead Sponsor ViiV Healthcare." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT05979311)) |
| April 15, 2026 | [ARD-101 primary completion](https://sec-api.dev/pdufa/ard-101) | AARD | Hyperphagia; Prader-Willi Syndrome; Hyperphagia in Prader-Willi Syndrome | withdrawn | "NCT07197034 (The Hunger Elimination or Reduction Objective (HERO ) Open -Label Extension (OLE) Trial): Overall Status TERMINATED; Phase PHASE3; Primary Completion 2026-04-15 (ACTUAL); Lead Sponsor Aardvark Therapeutics, Inc.." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07197034)) |
| April 15, 2026 | [WEZLANA® (ustekinumab) label expansion decision](https://sec-api.dev/pdufa/ustekinumab) | JNJ |  | completed, approved | "BLA761044 SUPPL-20 (Efficacy): submission_status AP, submission_status_date 20260415, review_priority STANDARD; sponsor_name JANSSEN BIOTECH; product STELARA (USTEKINUMAB)." ([openFDA Drugs@FDA](https://api.fda.gov/drug/drugsfda.json?search=application_number:%22BLA761044%22)) |
| April 16, 2026 | [ABBOTT LABORATORIES earnings report](https://sec-api.dev/companies/abt/catalysts) | ABT |  | completed | "Abbott Reports First-Quarter 2026 Results; Updates Guidance to Reflect Acquisition of Exact Sciences" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1800/000162828026025365/abt-2026q1xexhibitx991.htm)) |
| April 16, 2026 | [TAK-755 primary completion](https://sec-api.dev/pdufa/tak-755) | TAK | Thrombotic Thrombocytopenic Purpura (TTP) | completed | "NCT05714969 (A Study of TAK-755 (rADAMTS13) With Little to No Plasma Exchange (PEX) Treatment in Adults With Immune-mediated Thrombotic Thrombocytopenic Purpura (iTTP)): Overall Status COMPLETED; Phase PHASE2; Primary Completion 2026-04-16 (ACTUAL); Lead Sponsor Takeda." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT05714969)) |
| April 16, 2026 | [Retatrutide primary completion](https://sec-api.dev/pdufa/retatrutide) | LLY | Obesity; Cardiovascular Diseases | completed | "NCT05882045 (A Study of Retatrutide (LY3437943) in Participants With Obesity and Cardiovascular Disease): Overall Status COMPLETED; Phase PHASE3; Primary Completion 2026-04-16 (ACTUAL); Lead Sponsor Eli Lilly and Company." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT05882045)) |
| April 16, 2026 | [Nirsevimab topline data readout](https://sec-api.dev/pdufa/nirsevimab) | AZN | Respiratory Syncytial Virus Infections | completed | "NCT06042049 (A Study to Assess Safety, Pharmacokinetics Anti-Drug Antibody and Anti-RSV Antibody After 2 Doses of Nirsevimab): Overall Status COMPLETED; Phase PHASE3; Primary Completion 2025-07-24 (ACTUAL); Lead Sponsor AstraZeneca; Results First Posted 2026-04-16." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06042049?tab=results)) |
| April 17, 2026 | [Foscarbidopa primary completion](https://sec-api.dev/pdufa/foscarbidopa) | ABBV | Parkinson's Disease (PD) | completed | "NCT04379050 (Extension Study To Evaluate Safety And Tolerability Of 24-Hour Daily Exposure Of Continuous Subcutaneous Infusion of ABBV-951 In Adult Participants With Parkinson's Disease): Overall Status COMPLETED; Phase PHASE3; Primary Completion 2026-04-17 (ACTUAL); Lead Sponsor AbbVie." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT04379050)) |
| April 17, 2026 | [Bda mdi hfo 160/180 μg primary completion](https://sec-api.dev/pdufa/bda-mdi-hfo-160) | AZN | Asthma | completed | "NCT06502366 (A Study to Investigate the Effect on Lung Function of BDA Formulated With a Next Generation Propellant Compared With an Approved Asthma Treatment (BDA With HFA Propellant) in Participants With Asthma): Overall Status COMPLETED; Phase PHASE3; Primary Completion 2026-04-17 (ACTUAL); Lead Sponsor AstraZeneca." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06502366)) |
| April 17, 2026 | [Rocatinlimab primary completion](https://sec-api.dev/pdufa/rocatinlimab) | AMGN | Prurigo Nodularis | withdrawn | "NCT06527404 (A Phase 3, Placebo-controlled, Double-blind Study Assessing Rocatinlimab in Prurigo Nodularis): Overall Status TERMINATED; Phase PHASE3; Primary Completion 2026-04-17 (ACTUAL); Lead Sponsor Amgen." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06527404)) |
| April 17, 2026 | [Isl/len primary completion](https://sec-api.dev/pdufa/isl-len) | GILD | HIV-1-infection | completed | "NCT06630286 (Study to Compare an Oral Weekly Islatravir/Lenacapavir Regimen With Bictegravir/Emtricitabine/Tenofovir Alafenamide in Virologically Suppressed People With HIV-1): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2026-04-17 (ACTUAL); Lead Sponsor Gilead Sciences." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06630286)) |
| April 17, 2026 | [Cosentyx (secukinumab) label expansion decision](https://sec-api.dev/pdufa/secukinumab) | NVS |  | completed, approved | "BLA125504 SUPPL-97 (Efficacy): submission_status AP, submission_status_date 20260417, review_priority PRIORITY; sponsor_name NOVARTIS PHARMS CORP; product COSENTYX (SECUKINUMAB)." ([openFDA Drugs@FDA](https://api.fda.gov/drug/drugsfda.json?search=application_number:%22BLA125504%22)) |
| April 18, 2026 | [Mbx 1416 (inn imapextide) primary completion](https://sec-api.dev/pdufa/mbx-1416-inn-imapextide) | MBX | Postbariatric Hypoglycemia | completed | "NCT07029412 (Study to Evaluate Efficacy and Dose Response of Imapextide (STEADI)): Overall Status COMPLETED; Phase PHASE2; Primary Completion 2026-04-18 (ACTUAL); Lead Sponsor MBX Biosciences." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07029412)) |
| April 20, 2026 | [IDVYNSO (doravirine-islatravir) FDA approval](https://sec-api.dev/pdufa/doravirine-islatravir) | MRK |  | completed, approved | "Idvynso \| doravirine and islatravir \| 4/20/2026 \| To treat HIV-1 infection (as a complete regimen) in adults to replace the current antiretroviral regimen in those who are virologically-suppressed on a stable antiretroviral regimen with no history of virologic treatment failure and no known substitutions associated with resistance to doravirine" ([FDA novel drug approvals](https://www.fda.gov/drugs/novel-drug-approvals-fda/novel-drug-approvals-2026)) |
| April 21, 2026 | [Medpace Holdings, Inc. earnings report](https://sec-api.dev/companies/medp/catalysts) | MEDP |  | completed | "Medpace Holdings, Inc. Reports First Quarter 2026 Results" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1668397/000166839726000017/medp-20260422exx991.htm)) |
| April 21, 2026 | [Alhemo (concizumab) primary completion](https://sec-api.dev/pdufa/concizumab) | NVO | Haemophilia A and B With and Without Inhibitors | completed | "NCT05135559 (A Research Study on How Well Concizumab Works for You if You Have Haemophilia A or B With or Without Inhibitors): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2026-04-21 (ACTUAL); Lead Sponsor Novo Nordisk A/S." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT05135559)) |
| April 21, 2026 | [Zilovertamab vedotin primary completion](https://sec-api.dev/pdufa/zilovertamab-vedotin) | MRK | Relapsed or Refractory Diffuse Large B-Cell Lymphoma | completed | "NCT05144841 (A Study to Evaluate Zilovertamab Vedotin (MK-2140) for Relapsed or Refractory Diffuse Large B-Cell Lymphoma (DLBCL) (MK-2140-004)): Overall Status COMPLETED; Phase PHASE2; Primary Completion 2026-04-21 (ACTUAL); Lead Sponsor Merck Sharp & Dohme LLC." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT05144841)) |
| April 21, 2026 | [Fasedienol nasal spray primary completion](https://sec-api.dev/pdufa/fasedienol-nasal-spray) | VTGN | Social Anxiety Disorder (SAD) | completed | "NCT06615557 (Fasedienol Nasal Spray for the Acute Treatment of Anxiety in Adults With Social Anxiety Disorder (PALISADE-4)): Overall Status COMPLETED; Phase PHASE3; Primary Completion 2026-04-21 (ACTUAL); Lead Sponsor VistaGen Therapeutics, Inc.." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06615557)) |
| April 21, 2026 | [Tozorakimab primary completion](https://sec-api.dev/pdufa/tozorakimab) | AZN | Chronic Obstructive Pulmonary Disease (COPD) | completed | "NCT06897748 (A Study to Investigate Efficacy and Safety of Tozorakimab Injections Compared With Placebo in Adult Participants With Symptomatic Chronic Obstructive Pulmonary Disease (COPD) With a History of COPD Exacerbations and Elevated Eosinophils): Overall Status COMPLETED; Phase PHASE2; Primary Completion 2026-04-21 (ACTUAL); Lead Sponsor AstraZeneca." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06897748)) |
| April 22, 2026 | [Amneal Pharmaceuticals, Inc. earnings report](https://sec-api.dev/companies/amrx/catalysts) | AMRX |  | completed | "Reports Strong Preliminary First Quarter 2026 Financial Results and Raises FY2026 Standalone Guidance" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1723128/000119312526168231/d126526dex991.htm)) |
| April 22, 2026 | [AGN-151586 complete response letter (CRL)](https://sec-api.dev/pdufa/agn-151586) | ABBV |  | completed, complete response letter | "We have completed our review of this application, as amended, and have determined that we cannot approve this application in its present form." ([FDA complete response letter database](https://api.fda.gov/transparency/crl.json?search=file_name:%22CRL_BLA761459_20260422.pdf%22)) |
| April 22, 2026 | [Dupixent (dupilumab) label expansion decision](https://sec-api.dev/pdufa/dupilumab) | REGN |  | completed, approved | "BLA761055 SUPPL-74 (Efficacy): submission_status AP, submission_status_date 20260422, review_priority STANDARD; sponsor_name REGENERON PHARMACEUTICALS; product DUPIXENT (DUPILUMAB)." ([openFDA Drugs@FDA](https://api.fda.gov/drug/drugsfda.json?search=application_number:%22BLA761055%22)) |
| April 22, 2026 | [Wegovy (semaglutide) primary completion](https://sec-api.dev/pdufa/semaglutide) | NVO | Obesity | completed | "NCT06388187 (A Research Study to See How Well Different Doses of CagriSema Help People With Excess Body Weight Lose Weight): Overall Status COMPLETED; Phase PHASE3; Primary Completion 2026-04-22 (ACTUAL); Lead Sponsor Novo Nordisk A/S." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06388187)) |
| April 22, 2026 | [VRDN-003 primary completion](https://sec-api.dev/pdufa/vrdn-003) | VRDN | Thyroid Eye Disease (TED) | completed | "NCT06812325 (A Safety and Tolerability Study of VRDN-003 in Participants With Thyroid Eye Disease (TED)): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2026-04-22 (ACTUAL); Lead Sponsor Viridian Therapeutics, Inc.." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06812325)) |
| April 22, 2026 | [Zasocitinib primary completion](https://sec-api.dev/pdufa/zasocitinib) | TAK | Plaque Psoriasis | completed | "NCT06973291 (A Study Comparing Zasocitinib (TAK-279) With Deucravacitinib in Adults With Plaque Psoriasis): Overall Status COMPLETED; Phase PHASE3; Primary Completion 2026-04-22 (ACTUAL); Lead Sponsor Takeda." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06973291)) |
| April 23, 2026 | [Grace Therapeutics, Inc. complete response letter (CRL)](https://sec-api.dev/companies/grce/catalysts) | GRCE |  | completed, complete response letter | "April 23, 2026, the Company received a CRL from the FDA in response to their" ([SEC Form 10-K](https://www.sec.gov/Archives/edgar/data/1444192/000114036126025662/ef20070498_10k.htm)) |
| April 23, 2026 | [Fulcrum Therapeutics, Inc. earnings report](https://sec-api.dev/companies/fulc/catalysts) | FULC |  | completed | "Fulcrum Therapeutics Announces Recent Business Highlights and Financial Results for First Quarter 2026" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1680581/000119312526178806/fulc-ex99_1.htm)) |
| April 23, 2026 | [Grace Therapeutics, Inc. PDUFA date](https://sec-api.dev/companies/grce/catalysts) | GRCE |  | scheduled | "On August 22, 2025, the FDA accepted our NDA for review and established April 23, 2026 as the PDUFA target date for completing its review of our submission." ([SEC Form 10-Q](https://www.sec.gov/Archives/edgar/data/1444192/000114036126004924/ef20060621_10q.htm)) |
| April 23, 2026 | [Nimodipine NDA/BLA submission](https://sec-api.dev/pdufa/nimodipine) | GRCE |  | scheduled | "The FDA established a Prescription Drug User Fee Act (PDUFA) target date of April 23, 2026 for its review of the Company's NDA submission." ([SEC Form 8-K](https://www.sec.gov/Archives/edgar/data/1444192/000114036125032847/ef20054617_8k.htm)) |
| April 23, 2026 | [Psilocybin trial start](https://sec-api.dev/pdufa/psilocybin) | PBM | Adjustment Disorder in patients with cancer | completed | "Psyence Biomedical Ltd. (Nasdaq: PBM) ("Psyence BioMed" or the "Company"), a clinical-stage biopharmaceutical company developing nature-derived psychedelic therapeutics, today announced that the first patient has been dosed in its Phase IIb clinical trial evaluating NPX-5 (25mg of nature-derived psilocybin) for the treatment of Adjustment Disorder in patients with cancer in a palliative care setting." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1985062/000121390026047089/ea028743701ex99-1.htm)) |
| April 23, 2026 | [Nimodipine complete response letter (CRL)](https://sec-api.dev/pdufa/nimodipine) | GRCE | with aSAH | completed, complete response letter | "Princeton, NJ, April 23, 2026 (GLOBE NEWSWIRE)—Grace Therapeutics, Inc. (Nasdaq: GRCE) (Grace Therapeutics or the Company), a late-stage, biopharma company advancing GTx-104, a clinical-stage, novel, injectable formulation of nimodipine being developed for intravenous infusion to address significant unmet medical needs in aneurysmal subarachnoid hemorrhage (aSAH) patients, today announced that the U.S. Food and Drug Administration (FDA) has issued a Complete Response Letter (CRL) for the Company's New Drug Application (NDA) for GTx-104 for the treatment of patients with aSAH." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1444192/000114036126016324/ef20070593_ex99-1.htm)) |
| April 23, 2026 | [GTX-104 PDUFA date](https://sec-api.dev/pdufa/gtx-104) | GRCE | aSAH | completed, complete response letter | "FDA Established April 23, 2026 as PDUFA Target Date for Review of Submission Seeking Approval for GTx-104 in the Treatment of" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1444192/000114036126004927/ef20064916_ex99-1.htm)) |
| April 23, 2026 | [GTX-104 complete response letter (CRL)](https://sec-api.dev/pdufa/gtx-104) | GRCE | with aSAH | completed, complete response letter | "On April 23, 2026, the FDA issued a CRL for the Company's NDA for GTx-104 for the treatment of patients with aSAH." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1444192/000114036126025667/ef20076145_ex99-1.htm)) |
| April 23, 2026 | [Sanofi PDUFA date](https://sec-api.dev/companies/sny/catalysts) | SNY |  | scheduled | "The target action date for the FDA decision is April 23, 2026." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1121404/000119312525250744/d69958dex993.htm)) |
| April 23, 2026 | [Onasemnogene abeparvovec PDUFA date](https://sec-api.dev/pdufa/onasemnogene-abeparvovec) | IONS |  | scheduled | "The positive data generated from the DEVOTE study were the basis of the EU and Japan approvals and the regulatory submission in the U.S., which has an action date of April 23, 2026." ([SEC Form 10-K](https://www.sec.gov/Archives/edgar/data/874015/000087401526000115/form10k.htm)) |
| April 23, 2026 | [VOXZOGO (vosoritide) primary completion](https://sec-api.dev/pdufa/vosoritide) | BMRN | Hypochondroplasia | completed | "NCT06455059 (Interventional Study of Vosoritide for the Treatment of Children With Hypochondroplasia): Overall Status COMPLETED; Phase PHASE3; Primary Completion 2026-04-23 (ACTUAL); Lead Sponsor BioMarin Pharmaceutical." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06455059)) |
| April 23, 2026 | [Isl/len primary completion](https://sec-api.dev/pdufa/isl-len) | GILD | HIV-1-Infection | completed | "NCT06630299 (Study to Compare an Oral Weekly Islatravir/Lenacapavir Regimen With Standard of Care in Virologically Suppressed People With HIV-1): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2026-04-23 (ACTUAL); Lead Sponsor Gilead Sciences." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06630299)) |
| April 23, 2026 | [Rad101 (18f-fpia) primary completion](https://sec-api.dev/pdufa/rad101-18f-fpia) | RADX | Brain Metastases From Solid Tumors | completed | "NCT06777433 (Phase 2b Imaging Study of RAD101 in Participants With Suspected Recurrent Brain Metastases): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE2; Primary Completion 2026-04-23 (ACTUAL); Lead Sponsor Radiopharm Theranostics, Ltd." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06777433)) |
| April 23, 2026 | [Nda220304 complete response letter (CRL)](https://sec-api.dev/pdufa/nda220304) | GRCE |  | completed, complete response letter | "We have completed our review of this application, as amended, and have determined that we cannot approve this application in its present form." ([FDA complete response letter database](https://api.fda.gov/transparency/crl.json?search=file_name:%22CRL_NDA220304_20260423_Redacted.pdf%22)) |
| April 24, 2026 | [Saphnelo (anifrolumab-fnia) FDA approval](https://sec-api.dev/pdufa/anifrolumab-fnia) | AZN |  | completed, approved | "BLA761451 ORIG-1 (Type 5 - New Formulation or New Manufacturer): submission_status AP, submission_status_date 20260424, review_priority STANDARD; sponsor_name ASTRAZENECA AB; product SAPHNELO (ANIFROLUMAB-FNIA)." ([openFDA Drugs@FDA](https://api.fda.gov/drug/drugsfda.json?search=application_number:%22BLA761451%22)) |
| April 24, 2026 | [Keytruda Qlex (berahyaluronidase alfa-pmph; pembrolizumab) label expansion decision](https://sec-api.dev/pdufa/berahyaluronidase-alfa-pmph-pembrolizumab) | MRK |  | completed, approved | "BLA761467 SUPPL-3 (Efficacy): submission_status AP, submission_status_date 20260424, review_priority STANDARD; sponsor_name MERCK SHARP DOHME; product KEYTRUDA QLEX (BERAHYALURONIDASE ALFA-PMPH; PEMBROLIZUMAB)." ([openFDA Drugs@FDA](https://api.fda.gov/drug/drugsfda.json?search=application_number:%22BLA761467%22)) |
| April 24, 2026 | [Caplyta (lumateperone tosylate) label expansion decision](https://sec-api.dev/pdufa/lumateperone) | JNJ |  | completed, approved | "NDA209500 SUPPL-17 (Efficacy): submission_status AP, submission_status_date 20260424, review_priority STANDARD; sponsor_name INTRA-CELLULAR; product CAPLYTA (LUMATEPERONE TOSYLATE)." ([openFDA Drugs@FDA](https://api.fda.gov/drug/drugsfda.json?search=application_number:%22NDA209500%22)) |
| April 24, 2026 | [KEYTRUDA® (pembrolizumab) primary completion](https://sec-api.dev/pdufa/pembrolizumab) | MRK | Breast Neoplasms | completed | "NCT04895358 (Study of Pembrolizumab (MK-3475) Plus Chemotherapy Versus Placebo Plus Chemotherapy for HR+/HER2- Locally Recurrent Inoperable or Metastatic Breast Cancer (MK-3475-B49/KEYNOTE-B49)): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2026-04-24 (ACTUAL); Lead Sponsor Merck Sharp & Dohme LLC." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT04895358)) |
| April 27, 2026 | [ORKA-001 interim data readout](https://sec-api.dev/pdufa/orka-001) | ORKA | chronic skin diseases, today | completed, positive | "-- Oruka Therapeutics, Inc. ("Oruka") (Nasdaq: ORKA), a clinical-stage biotechnology company developing novel biologics designed to set a new standard for the treatment of chronic skin diseases, today announced positive interim results from its EVERLAST-A Phase 2a trial of ORKA-001, a novel half-life extended IL-23p19 monoclonal antibody, in moderate-to-severe plaque psoriasis." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/907654/000121390026047743/ea028778201ex99-1.htm)) |
| April 27, 2026 | [ET-700 trial start](https://sec-api.dev/pdufa/et-700) | ETON | Wilson disease | completed | "DEER PARK, Ill., April 27, 2026 (GLOBE NEWSWIRE) -- Eton Pharmaceuticals, Inc ("Eton" or "the Company") (Nasdaq: ETON), an innovative pharmaceutical company focused on developing and commercializing treatments for rare diseases, today announced the first patient has been dosed in a pilot clinical study assessing the efficacy of ET-700, the Company's proprietary, patent-pending formulation of extended-release zinc acetate under development for the treatment of Wilson disease." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1710340/000143774926013369/ex_940424.htm)) |
| April 27, 2026 | [Veradermics, Inc topline data readout](https://sec-api.dev/companies/mane/catalysts) | MANE |  | completed, positive | "On April 27, 2026, the Company announced positive topline data from the Phase 2/3 clinical trial, Study '302' evaluating VDPHL01 in males with mild-to-moderate pattern hair loss." ([SEC Form 8-K](https://www.sec.gov/Archives/edgar/data/1827635/000162828026027354/mane-20260427.htm)) |
| April 27, 2026 | [REZZAYO® (rezafungin) topline data readout](https://sec-api.dev/pdufa/rezafungin) | CRMD |  | completed, positive | "•On April 27, 2026, CorMedix announced positive Phase III topline results from the global ReSPECT clinical trial evaluating REZZAYO® (rezafungin for injection) for prophylaxis of invasive fungal diseases in adult patients undergoing allogeneic hematopoietic stem cell transplantation." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1410098/000141009826000020/crmd_q12026earningspr.htm)) |
| April 27, 2026 | [Breztri Aerosphere (budesonide; formoterol fumarate; glycopyrrolate) label expansion decision](https://sec-api.dev/pdufa/budesonide-formoterol-glycopyrrolate) | AZN |  | completed, approved | "NDA212122 SUPPL-9 (Efficacy): submission_status AP, submission_status_date 20260427, review_priority STANDARD; sponsor_name ASTRAZENECA AB; product BREZTRI AEROSPHERE (BUDESONIDE; FORMOTEROL FUMARATE; GLYCOPYRROLATE)." ([openFDA Drugs@FDA](https://api.fda.gov/drug/drugsfda.json?search=application_number:%22NDA212122%22)) |
| April 27, 2026 | [Symbicort Aerosphere (budesonide; formoterol fumarate) label expansion decision](https://sec-api.dev/pdufa/budesonide-formoterol) | AZN |  | completed, approved | "NDA216579 SUPPL-1 (Efficacy): submission_status AP, submission_status_date 20260427, review_priority STANDARD; sponsor_name ASTRAZENECA; product SYMBICORT AEROSPHERE (BUDESONIDE; FORMOTEROL FUMARATE)." ([openFDA Drugs@FDA](https://api.fda.gov/drug/drugsfda.json?search=application_number:%22NDA216579%22)) |
| April 27, 2026 | [Sanofi PDUFA date](https://sec-api.dev/companies/sny/catalysts) | SNY |  | scheduled | "The target action date for the FDA decision is April 27, 2026." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1121404/000119312525250744/d69958dex993.htm)) |
| April 27, 2026 | [BRUKINSA® (zanubrutinib) primary completion](https://sec-api.dev/pdufa/zanubrutinib) | ONC | Mantle Cell Lymphoma; Non-Hodgkin Lymphoma | completed | "NCT04002297 (A Study to Investigate the Efficacy of Zanubrutinib Plus Rituximab Compared With Bendamustine Plus Rituximab in Adults With Previously Untreated Mantle Cell Lymphoma Who Are Ineligible for Stem Cell Transplantation): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2026-04-27 (ACTUAL); Lead Sponsor BeOne Medicines." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT04002297)) |
| April 27, 2026 | [Foscarbidopa primary completion](https://sec-api.dev/pdufa/foscarbidopa) | ABBV | Parkinson's Disease (PD) | completed | "NCT04750226 (Study To Assess Adverse Events and Change in Disease Activity Of 24-hour Continuous Subcutaneous Infusion Of ABBV-951 In Adult Participants With Advanced Parkinson's Disease): Overall Status COMPLETED; Phase PHASE3; Primary Completion 2026-04-27 (ACTUAL); Lead Sponsor AbbVie." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT04750226)) |
| April 2026 | [Berubicin primary completion](https://sec-api.dev/pdufa/berubicin) | CNSP | Glioblastoma Multiforme, Adult | delayed | "NCT04762069 (A Study of Berubicin in Adult Subjects With Recurrent Glioblastoma Multiforme): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE2; Primary Completion 2026-04-27 (ESTIMATED); Lead Sponsor CNS Pharmaceuticals, Inc.." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT04762069)) |
| April 27, 2026 | [Botvymo® (botensilimab) primary completion](https://sec-api.dev/pdufa/botensilimab) | AGEN | Advanced Melanoma | withdrawn | "NCT05529316 (A Study of Botensilimab (AGEN1181) for the Treatment of Advanced Melanoma): Overall Status TERMINATED; Phase PHASE2; Primary Completion 2026-04-27 (ACTUAL); Lead Sponsor Agenus Inc.." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT05529316)) |
| April 28, 2026 | [Kiniksa Pharmaceuticals International, plc earnings report](https://sec-api.dev/companies/knsa/catalysts) | KNSA |  | completed | "Kiniksa Pharmaceuticals Reports First Quarter 2026 Financial Results and Recent Portfolio Execution" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1730430/000173043026000017/knsa-20260428xex99d1.htm)) |
| April 28, 2026 | [Wave Life Sciences, Inc. earnings report](https://sec-api.dev/companies/wve/catalysts) | WVE |  | completed | "Wave Life Sciences Reports First Quarter 2026 Financial Results and Provides Business Update" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1631574/000119312526183563/d135689dex991.htm)) |
| April 28, 2026 | [OPKO HEALTH, INC. earnings report](https://sec-api.dev/companies/opk/catalysts) | OPK |  | completed | "OPKO Health Reports First Quarter 2026 Business Highlights and Financial Results" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/944809/000119312526186939/opk-ex99_1.htm)) |
| April 28, 2026 | [INCYTE CORP earnings report](https://sec-api.dev/companies/incy/catalysts) | INCY |  | completed | "Incyte Reports First Quarter 2026 Financial Results and Provides Business Updates" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/879169/000087916926000023/incy-q12026xexx991.htm)) |
| April 28, 2026 | [Design Therapeutics, Inc. earnings report](https://sec-api.dev/companies/dsgn/catalysts) | DSGN |  | completed | "Design Therapeutics Announces First Quarter 2026 Financial Results and Recent Business Updates" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1807120/000119312526187012/dsgn-ex99_1.htm)) |
| April 28, 2026 | [IDVYNSO (doravirine-islatravir) PDUFA date](https://sec-api.dev/pdufa/doravirine-islatravir) | MRK |  | completed, approved | "The FDA set a PDUFA, or target action, date of April 28, 2026 for the new drug application, which is based on findings of the Phase 3 MK-8591A-051 and MK-8591A-052 clinical trials." ([SEC Form 10-K](https://www.sec.gov/Archives/edgar/data/310158/000031015826000063/mrk-20251231.htm)) |
| April 28, 2026 | [NRC HEALTH earnings report](https://sec-api.dev/companies/nrc/catalysts) | NRC |  | completed | "NRC HEALTH ANNOUNCES FIRST QUARTER 2026 RESULTS" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/70487/000143774926013641/ex_950648.htm)) |
| April 28, 2026 | [Votoplam topline data readout](https://sec-api.dev/pdufa/votoplam) | PTCT |  | completed, positive | "On April 28, 2026, PTC Therapeutics, Inc. (the "Company") reported positive topline results from the 24-month interim analysis of the PIVOT-HD long-term extension study of votoplam." ([SEC Form 8-K](https://www.sec.gov/Archives/edgar/data/1070081/000107008126000006/tmb-20260428x8k.htm)) |
| April 28, 2026 | [Obefazimod primary completion](https://sec-api.dev/pdufa/obefazimod) | ABVX | Ulcerative Colitis | completed | "NCT05535946 (ABTECT - Maintenance): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2026-04-28 (ACTUAL); Lead Sponsor Abivax S.A.." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT05535946)) |
| April 28, 2026 | [HZN-1116 primary completion](https://sec-api.dev/pdufa/hzn-1116) | AMGN | Sjogren's Syndrome | withdrawn | "NCT06312020 (A Phase 2 Study to Investigate Efficacy and Safety of HZN-1116 in Participants With Sjogren's Syndrome): Overall Status TERMINATED; Phase PHASE2; Primary Completion 2026-04-28 (ACTUAL); Lead Sponsor Amgen." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06312020)) |
| April 29, 2026 | [Sanofi PDUFA date](https://sec-api.dev/companies/sny/catalysts) | SNY |  | delayed | "The target action date is April 29, 2026." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1121404/000112140426000001/pressreleaseq42025english.htm)) |
| April 29, 2026 | [REGENERON PHARMACEUTICALS, INC. earnings report](https://sec-api.dev/companies/regn/catalysts) | REGN |  | completed | "Tarrytown, New York (April 29, 2026) -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced financial results for the first quarter of 2026 and provided a business update." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/872589/000087258926000014/exhibit991q12026.htm)) |
| April 29, 2026 | [BIOGEN INC. earnings report](https://sec-api.dev/companies/biib/catalysts) | BIIB |  | completed | "Biogen reports strong first quarter 2026 results" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/875045/000087504526000042/exhibit991-q12026pressrele.htm)) |
| April 29, 2026 | [CRESCENT BIOPHARMA, INC. earnings report](https://sec-api.dev/companies/cbio/catalysts) | CBIO |  | completed | "Crescent Biopharma Reports First Quarter 2026 Financial Results and Recent Business Highlights" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1253689/000162828026028386/pressrelease-livefile.htm)) |
| April 29, 2026 | [Rapamycin PDUFA date](https://sec-api.dev/pdufa/rapamycin) | LGND |  | scheduled | "The target action date for the FDA decision is April 29, 2026." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/886163/000088616326000003/q42025earningsrelease_ex991.htm)) |
| April 29, 2026 | [AbbVie Inc. earnings report](https://sec-api.dev/companies/abbv/catalysts) | ABBV |  | completed | "AbbVie Reports First-Quarter 2026 Financial Results" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1551152/000155115226000013/abbv-20260331xexhibit991.htm)) |
| April 29, 2026 | [AMARIN CORP PLCUK earnings report](https://sec-api.dev/companies/amrn/catalysts) | AMRN |  | completed | "Amarin Reports 2026 First Quarter Financial Results" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/897448/000119312526188935/amrn-ex99_1.htm)) |
| April 29, 2026 | [Viking Therapeutics, Inc. earnings report](https://sec-api.dev/companies/vktx/catalysts) | VKTX |  | completed | "Viking Therapeutics Reports First Quarter 2026 Financial Results and Provides Corporate Update" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1607678/000119312526191487/vktx-ex99_1.htm)) |
| April 29, 2026 | [AbbVie Inc. complete response letter (CRL)](https://sec-api.dev/companies/abbv/catalysts) | ABBV |  | completed, complete response letter | "•AbbVie announced it received a Complete Response Letter (CRL) from the FDA regarding the Biologics License Application (BLA) for trenibotulinumtoxinE (trenibotE), a first-in-class botulinum neurotoxin serotype E with a rapid onset of effect and short duration." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1551152/000155115226000013/abbv-20260331xexhibit991.htm)) |
| April 29, 2026 | [AGIOS PHARMACEUTICALS, INC. earnings report](https://sec-api.dev/companies/agio/catalysts) | AGIO |  | completed | "Agios Reports First Quarter 2026 Financial Results and Provides Business Update" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1439222/000143922226000071/agio-42926xfyxex991earning.htm)) |
| April 29, 2026 | [Bausch Health Companies Inc. earnings report](https://sec-api.dev/companies/bhc/catalysts) | BHC |  | completed | "BAUSCH HEALTH ANNOUNCES FIRST QUARTER 2026 RESULTS" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/885590/000088559026000051/ex991-q1x2026.htm)) |
| April 29, 2026 | [TEVA PHARMACEUTICAL INDUSTRIES LTD earnings report](https://sec-api.dev/companies/teva/catalysts) | TEVA |  | completed | "TEL AVIV, Israel, April 29, 2026 (GLOBE NEWSWIRE) -- Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) today reported results for the quarter ended March 31, 2026." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/818686/000117184326002796/exh_991.htm)) |
| April 29, 2026 | [IONIS PHARMACEUTICALS INC earnings report](https://sec-api.dev/companies/ions/catalysts) | IONS |  | completed | "Ionis reports first quarter 2026 financial results and highlights progress on key programs" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/874015/000114036126017637/ef20071749_ex99-1.htm)) |
| April 29, 2026 | [CERUS CORP primary completion](https://sec-api.dev/companies/cers/catalysts) | CERS | Anemia | completed | "NCT03037164 (INTERCEPT Blood System for RBCs Study in Regions at Potential Risk for Zika Virus Transfusion-Transmitted Infections): Overall Status COMPLETED; Phase PHASE3; Primary Completion 2026-04-29 (ACTUAL); Lead Sponsor Cerus Corporation." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT03037164)) |
| April 2026 | [Otx-tki (axitinib implant) primary completion](https://sec-api.dev/pdufa/otx-tki-axitinib-implant) | OCUL | Neovascular Age-Related Macular Degeneration | delayed | "NCT06223958 (Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (Axitinib Implant) in Subjects With Neovascular Age-Related Macular Degeneration): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2026-04-29 (ESTIMATED); Lead Sponsor Ocular Therapeutix, Inc.." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06223958)) |
| April 29, 2026 | [0.454%stannous fluoride toothpaste primary completion](https://sec-api.dev/pdufa/0-454-stannous-fluoride-toothpaste) | CL | Plaque | completed | "NCT07398846 (Efficacy of a Stannous Fluoride Toothpaste, Cetylpyridinium Chloride Mouthwash, and Battery Toothbrush Regimen in Reducing Established Dental Plaque and Gingivitis.): Overall Status COMPLETED; Phase PHASE3; Primary Completion 2026-04-29 (ACTUAL); Lead Sponsor Colgate Palmolive." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07398846)) |
| April 30, 2026 | [AUVELITY (dextromethorphan-bupropion) label expansion decision](https://sec-api.dev/pdufa/dextromethorphan-bupropion) | AXSM | agitation associated with dementia due to Alzheimer's disease | completed, approved | "AUVELITY was approved by the FDA for the treatment of agitation associated with dementia due to Alzheimer's disease on April 30, 2026 Acceleration in prescription trends among patients aged 65+ following ADA label expansion, alongside continued growth for under 65 FDA approval FDA approval" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1579428/000119312526442628/axsm-ex99_2.htm)) |
| April 30, 2026 | [Merck & Co., Inc. earnings report](https://sec-api.dev/companies/mrk/catalysts) | MRK |  | completed | "Co., Inc., Rahway, N.J., USA Announces First-Quarter 2026 Financial Results; Highlights Significant Regulatory Approvals and Clinical" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/310158/000110465926052081/tm2612241d1_ex99-1.htm)) |
| April 30, 2026 | [ACI-24 trial start](https://sec-api.dev/pdufa/aci-24) | ACIU | Alzheimer's Disease triggers milestone payment, as | completed | "Initiated final cohort, AD4, in ABATE Phase 1b/2 trial of ACI-24 to treat Alzheimer's Disease triggers milestone payment, as announced separately today" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1651625/000095010326006499/dp245995_ex9901.htm)) |
| April 30, 2026 | [Kymera Therapeutics, Inc. earnings report](https://sec-api.dev/companies/kymr/catalysts) | KYMR |  | completed | "Kymera Therapeutics Announces First Quarter 2026 Financial Results and Provides a Business Update" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1815442/000119312526193957/kymr-ex99_1.htm)) |
| April 30, 2026 | [SYMBRAVO® (meloxicam-rizatriptan) PDUFA date](https://sec-api.dev/pdufa/meloxicam-rizatriptan) | AXSM |  | scheduled | "SYMBRAVO® 4Q and full year 2025 net product sales of $4.1 million and $6.6 million, respectively sNDA for AXS-05 for the treatment of Alzheimer's disease agitation granted Priority Review with PDUFA target action date of April 30, 2026" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1579428/000119312526062421/axsm-ex99_1.htm)) |
| April 30, 2026 | [ALNYLAM PHARMACEUTICALS, INC. earnings report](https://sec-api.dev/companies/alny/catalysts) | ALNY |  | completed | "Alnylam Pharmaceuticals Reports First Quarter 2026 Financial Results and Highlights Recent Period Progress" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1178670/000162828026028601/alny2026q1earningsrelease.htm)) |
| April 30, 2026 | [Syndax Pharmaceuticals Inc earnings report](https://sec-api.dev/companies/sndx/catalysts) | SNDX |  | completed | "Syndax Reports First Quarter 2026 Financial Results and Provides Business Update" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1395937/000119312526197124/sndx-ex99_1.htm)) |
| April 30, 2026 | [ARDELYX, INC. earnings report](https://sec-api.dev/companies/ardx/catalysts) | ARDX |  | completed | "Ardelyx Reports First Quarter 2026 Financial Results and Provides Business Update" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1437402/000143740226000021/ardx-20260331xexhibit991.htm)) |
| April 30, 2026 | [BICYCLE THERAPEUTICS PLC earnings report](https://sec-api.dev/companies/bcyc/catalysts) | BCYC |  | completed | "- Bicycle Therapeutics plc (NASDAQ: BCYC), a pharmaceutical company pioneering a new and differentiated class of therapeutics based on its proprietary bicyclic peptide (Bicycle®) technology, today reported financial results for the first quarter ended" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1761612/000110465926052107/tm2613019d1_ex99-1.htm)) |
| April 30, 2026 | [AUVELITY (dextromethorphan-bupropion) FDA approval](https://sec-api.dev/pdufa/dextromethorphan-bupropion) | AXSM | agitation associated with dementia due to Alzheimer's disease | completed, approved | "On April 30, 2026, Axsome Therapeutics, Inc. (the "Company") issued a press release announcing that the U.S. Food and Drug Administration (FDA) has approved AUVELITY® for the treatment of agitation associated with dementia due to Alzheimer's disease." ([SEC Form 8-K](https://www.sec.gov/Archives/edgar/data/1579428/000119312526197857/axsm-20260430.htm)) |
| April 30, 2026 | [Phathom Pharmaceuticals, Inc. earnings report](https://sec-api.dev/companies/phat/catalysts) | PHAT |  | completed | "Phathom Pharmaceuticals Reports First Quarter 2026 Financial Results and Provides Business Update" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1783183/000119312526193945/d140332dex991.htm)) |
| April 30, 2026 | [Supernus, Inc. earnings report](https://sec-api.dev/companies/supn/catalysts) | SUPN |  | completed | "Indivior Reports First Quarter 2026 Financial Results and Raises Full-Year 2026 Guidance" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1625297/000119312526193925/d40828dex991.htm)) |
| April 30, 2026 | [Pacira BioSciences, Inc. earnings report](https://sec-api.dev/companies/pcrx/catalysts) | PCRX |  | completed | "Pacira BioSciences Reports First Quarter 2026 Financial Results" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1396814/000162828026028854/pcrx-03312026x991.htm)) |
| April 30, 2026 | [AMGEN INC earnings report](https://sec-api.dev/companies/amgn/catalysts) | AMGN |  | completed | "AMGEN REPORTS FIRST QUARTER 2026 FINANCIAL RESULTS" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/318154/000031815426000054/amgn-20260331earningsrelea.htm)) |
| April 30, 2026 | [Corcept earnings report](https://sec-api.dev/pdufa/corcept) | CORT |  | completed | "Corcept Therapeutics Announces First Quarter Financial Results and Provides Corporate Update" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1088856/000162828026028892/cort043026ex991pressrelease.htm)) |
| April 30, 2026 | [ELI LILLY & Co earnings report](https://sec-api.dev/companies/lly/catalysts) | LLY |  | completed | "Lilly reports first-quarter 2026 financial results, raises full year guidance, and highlights momentum of new medicines" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/59478/000005947826000043/q126lillysalesandearningsp.htm)) |
| April 30, 2026 | [Summit Therapeutics Inc. earnings report](https://sec-api.dev/companies/smmt/catalysts) | SMMT |  | completed | "1 Summit Therapeutics Reports Financial Results and Operational Progress for the First Quarter Ended March 31, 2026 Overall Survival Data to be Featured at ASCO 2026 Plenary Session as Late-Breaking Abstract from HARMONi-6, a Phase III Study in 1L Squamous NSCLC in China Update Conference Call to be Held on June 1, 2026 after ASCO Plenary Session HARMONi-3 Squamous Cohort of Global Phase III 1L NSCLC Study: Final PFS Data Expected in Second Half of 2026 with Interim OS Analyses Planned HARMONi-3 Non-Squamous Cohort of Global Phase III 1L NSCLC Study: PFS Data Expected in the First Half 2027 Miami, Florida, April 30, 2026 - Summit Therapeutics Inc. (NASDAQ: SMMT) ("Summit," "we," or the "Company") today reports its financial results and provides an update on clinical and operational progress for the first quarter ended March 31, 2026." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1599298/000159929826000037/a2026_prx0506xq12026earn.htm)) |
| April 30, 2026 | [Emergent BioSolutions Inc. earnings report](https://sec-api.dev/companies/ebs/catalysts) | EBS |  | completed | "EMERGENT BIOSOLUTIONS REPORTS FIRST QUARTER 2026 FINANCIAL RESULTS" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1367644/000136764426000059/ebs20260331ex99er.htm)) |
| April 30, 2026 | [BRISTOL MYERS SQUIBB CO earnings report](https://sec-api.dev/companies/bmy/catalysts) | BMY |  | completed | "Bristol Myers Squibb Reports First Quarter Financial Results for 2026" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/14272/000001427226000008/a2026q1ex991.htm)) |
| April 30, 2026 | [Pipe-791 dose a topline data readout](https://sec-api.dev/pdufa/pipe-791) | CTNM |  | completed, positive | "•On April 30, 2026, the Company reported positive topline data from its exploratory Phase 1b trial of PIPE-791 for the non-opioid treatment of chronic osteoarthritis pain or chronic low back pain." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1855175/000162828026051051/q220268kex991.htm)) |
| April 30, 2026 | [Organon & Co. earnings report](https://sec-api.dev/companies/ogn/catalysts) | OGN |  | completed | "Organon Reports Results for the First Quarter" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1821825/000110465926052165/tm2613165d1_ex99-1.htm)) |
| April 30, 2026 | [Auvelity (bupropion hydrochloride; dextromethorphan hydrobromide) label expansion decision](https://sec-api.dev/pdufa/bupropion-dextromethorphan) | AXSM |  | completed, approved | "NDA215430 SUPPL-18 (Efficacy): submission_status AP, submission_status_date 20260430, review_priority PRIORITY; sponsor_name AXSOME; product AUVELITY (BUPROPION HYDROCHLORIDE; DEXTROMETHORPHAN HYDROBROMIDE)." ([openFDA Drugs@FDA](https://api.fda.gov/drug/drugsfda.json?search=application_number:%22NDA215430%22)) |
| April 30, 2026 | [Etcamah (camizestrant) FDA advisory committee meeting](https://sec-api.dev/pdufa/camizestrant) | AZN |  | completed, negative | "On the morning of April 30, 2026, the Committee will discuss new drug application (NDA) 220359, for camizestrant tablets, submitted by AstraZeneca Pharmaceuticals LP. The proposed indication (use) is in combination with a CDK4/6 inhibitor (palbociclib, ribociclib or abemaciclib) for the treatment of adult patients with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative, locally advanced or metastatic breast cancer upon emergence of ESR1 mutation during first-line endocrine-based therapy, based on an FDA approved test." ([FDA advisory committee calendar](https://www.fda.gov/advisory-committees/advisory-committee-calendar/april-30-2026-meeting-oncologic-drugs-advisory-committee-meeting-announcement-04302026)) |
| April 30, 2026 | [Truqap (capivasertib) FDA advisory committee meeting](https://sec-api.dev/pdufa/capivasertib) | AZN |  | completed, positive | "On the afternoon of April 30, 2026, the Committee will discuss supplemental new drug application (sNDA) 218197/S-004, for Truqap (capivasertib) tablets, submitted by AstraZeneca Pharmaceuticals LP. The proposed indication (use) is in combination with abiraterone for the treatment of adult patients with metastatic hormone-sensitive prostate cancer (mHSPC) that is PTEN-deficient as detected by an FDA-approved test." ([FDA advisory committee calendar](https://www.fda.gov/advisory-committees/advisory-committee-calendar/april-30-2026-meeting-oncologic-drugs-advisory-committee-meeting-announcement-04302026)) |
| April 30, 2026 | [Cartesian Therapeutics, Inc. earnings report](https://sec-api.dev/companies/rnac/catalysts) | RNAC |  | completed | "Cartesian Therapeutics Reports First Quarter 2026 Financial Results and Provides Business Update" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1453687/000145368726000081/exhibit991_earningsrelease.htm)) |
| April 30, 2026 | [AUVELITY (dextromethorphan-bupropion) PDUFA date](https://sec-api.dev/pdufa/dextromethorphan-bupropion) | AXSM |  | completed, approved | "AXS-05 for Alzheimer's disease agitation, PDUFA target action (April 30, 2026)" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1579428/000119312526062421/axsm-ex99_1.htm)) |
| April 30, 2026 | [DBV Technologies S.A. earnings report](https://sec-api.dev/companies/dbvt/catalysts) | DBVT |  | completed | "DBV Technologies Reports First Quarter 2026 Financial Results" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1613780/000119312526197921/d132063dex991.htm)) |
| April 30, 2026 | [Entyvio® (vedolizumab) topline data readout](https://sec-api.dev/pdufa/vedolizumab) | TAK | Colitis, Ulcerative | completed | "NCT04779307 (A Study of Vedolizumab in Children and Teenagers With Moderate to Severe Ulcerative Colitis (UC)): Overall Status COMPLETED; Phase PHASE3; Primary Completion 2025-07-01 (ACTUAL); Lead Sponsor Takeda; Results First Posted 2026-04-30." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT04779307?tab=results)) |
| April 30, 2026 | [AZD7798 primary completion](https://sec-api.dev/pdufa/azd7798) | AZN | Moderate to Severe Crohn's Disease | completed | "NCT06450197 (Phase IIa Study Evaluating AZD7798 in Crohn's Disease): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE2; Primary Completion 2026-04-30 (ACTUAL); Lead Sponsor AstraZeneca." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06450197)) |
| April 2026 | [Foralumab tzls-401 100 µg primary completion](https://sec-api.dev/pdufa/foralumab-tzls-401) | TLSA | Non-Active Secondary Progressive Multiple Sclerosis | delayed | "NCT06890923 (Nasal Foralumab in Patients With Non-Active Secondary Progressive Multiple Sclerosis): Overall Status RECRUITING; Phase PHASE2; Primary Completion 2026-04-30 (ESTIMATED); Lead Sponsor Tiziana Life Sciences LTD." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06890923)) |

Other months: https://sec-api.dev/fda-calendar/2026-03 , https://sec-api.dev/fda-calendar/2026-05. Calendar: https://sec-api.dev/fda-calendar

## Feeds and downloads

- Next 30 days as CSV: https://sec-api.dev/fda-calendar.csv . JSON: https://sec-api.dev/fda-calendar.json . All events (iCal): https://sec-api.dev/fda-calendar.ics
- New or moved PDUFA dates: https://sec-api.dev/pdufa-dates/feed.xml (RSS), https://sec-api.dev/pdufa-dates/feed.json (JSON Feed)
- FDA approvals: https://sec-api.dev/fda-approvals-today/feed.xml (RSS), https://sec-api.dev/fda-approvals-today/feed.json (JSON Feed)
- License: CC BY 4.0 for the public 30-day window (https://sec-api.dev/biotech/license.txt). Full history: https://sec-api.dev/pricing

## Cite this page

sec-api.dev. "PDUFA dates April 2026: FDA calendar and catalysts." Biotech catalyst calendar, data as of November 16, 2026 (snapshot 20261116T222116Z). https://sec-api.dev/fda-calendar/2026-04

```bibtex
@misc{secapidev_fda_calendar_2026_04_20261116,
  title        = {PDUFA dates April 2026: FDA calendar and catalysts},
  author       = {{sec-api.dev}},
  year         = {2026},
  month        = {nov},
  howpublished = {\url{https://sec-api.dev/fda-calendar/2026-04}},
  note         = {Biotech catalyst calendar, data as of 2026-11-16, snapshot 20261116T222116Z. Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source.}
}
```

```json
{"type":"dataset","id":"secapidev_fda_calendar_2026_04_20261116","title":"PDUFA dates April 2026: FDA calendar and catalysts","publisher":"sec-api.dev","URL":"https://sec-api.dev/fda-calendar/2026-04","issued":{"date-parts":[[2026,11,16]]},"version":"20261116T222116Z","license":"https://creativecommons.org/licenses/by/4.0/","note":"Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source."}
```

---
Independent. Not affiliated with, endorsed by, or sponsored by the U.S. Food and Drug Administration or the U.S. Securities and Exchange Commission. Dates are as stated by sponsors and FDA; the FDA can act before or after a target date. Not investment advice.
